| 摘要 |
The invention concerns compounds that modulate Placenta Growth Factor activity and the use of such compounds for the manufacture of a medicament for treating conditions at least partially characterised by abnormal ocular angiogenesis such as retinal neovascularisation, subretinal neovascularisation, glaucomatous neovascularisation, rubeosis or corneal neovascularisation. These conditions include Vasoproliferative Retinopathy, especially Proliferative Diabetic Retinopathy. |
